What Does Glucagon Do in Retatrutide?

Glucagon is one of three hormones targeted by retatrutide, an investigational triple-receptor agonist that has no marketing authorisation in the UK or elsewhere. Understanding what glucagon does in retatrutide's mechanism helps clarify how this medicine differs from currently licensed treatments. Alongside GLP-1 and GIP receptor activation, glucagon receptor stimulation is thought to influence hepatic fat metabolism and energy expenditure. This article explains the role of glucagon within retatrutide's proposed mechanism, summarises what clinical trial data have reported, and outlines the safety considerations relevant to anyone participating in an authorised trial.

What is retatrutide and how does it work in the body?

Retatrutide is an investigational triple agonist activating GLP-1, GIP and glucagon receptors simultaneously. It holds no marketing authorisation and is available only within authorised clinical trials.

Retatrutide is an investigational medicine that simultaneously activates three hormone receptors, namely the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor, making it a triple agonist. It holds no marketing authorisation in the UK or anywhere else, and it is administered or dispensed only under a clinical trial protocol by the trial team.^[3] No launch date or timeline can be given.

The three hormones that retatrutide mimics are all naturally occurring peptides involved in regulating appetite, blood glucose and energy expenditure. By engaging all three receptors at once, the molecule is designed to influence several metabolic pathways simultaneously rather than targeting a single signalling route. This distinguishes it mechanistically from currently authorised medicines such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP and GLP-1 receptor agonist), though no head-to-head trials have been conducted.^[4][5]

Because retatrutide is not authorised, it cannot be obtained through a pharmacy or private clinic. Anyone who encounters a product sold online under this name should be aware that it is not a licensed medicine and may be falsified or unsafe. Individuals interested in licensed weight-management treatments can discuss the options that are currently available with their GP.

What role does glucagon play in retatrutide's triple-receptor action?

Glucagon receptor activation is considered the component most likely to stimulate energy expenditure and hepatic fat metabolism, complementing the appetite-suppressing and insulin-sensitising effects of the GLP-1 and GIP receptor arms.

In retatrutide's proposed mechanism, glucagon receptor activation is the component considered most likely to stimulate energy expenditure and hepatic fat metabolism, complementing the appetite-suppressing and insulin-sensitising effects driven by the GLP-1 and GIP receptor arms. These mechanistic roles are based on preclinical data and early human evidence and have not yet been fully confirmed in large-scale trials. Glucagon is a peptide hormone secreted by the alpha cells of the pancreatic islets, and its primary physiological role is to raise blood glucose by stimulating the liver to release stored glucose through glycogenolysis and to produce new glucose through gluconeogenesis.

In the context of a triple agonist, the glucagon receptor component introduces a metabolic dimension that pure GLP-1 agonists do not provide. Specifically, preclinical and early human data suggest that glucagon signalling in the liver promotes the breakdown of fatty acids (beta-oxidation) and may reduce hepatic lipid accumulation.^[13][22] These effects have attracted research interest in conditions such as metabolic-associated steatotic liver disease, though retatrutide is investigational and holds no authorised indication for any condition. In adipose tissue, preclinical evidence suggests that glucagon receptor activation may increase thermogenesis, the process by which cells generate heat rather than storing energy as fat, but the extent to which this translates to humans is still being investigated.

A theoretical concern with glucagon receptor activation is that it could raise blood glucose, which would be counterproductive in people with type 2 diabetes. Researchers designing retatrutide balanced this by pairing glucagon receptor agonism with robust GLP-1 receptor stimulation, which promotes insulin secretion in a glucose-dependent manner and is expected to offset any hyperglycaemic tendency.^[4][6] How this balance performs across different patient populations, and at different doses, remains a subject of ongoing investigation within authorised trials.

How does activating the glucagon receptor affect metabolism?

Glucagon receptor activation increases hepatic fat oxidation and may reduce liver triglyceride content by amplifying fasting-like metabolic signals via cyclic AMP signalling pathways.

Based on preclinical and early human evidence, glucagon receptor activation increases the liver's rate of fat oxidation and may reduce hepatic triglyceride content, effects that go beyond simple blood glucose regulation. In normal physiology, glucagon rises during fasting and exercise, signalling the liver to mobilise energy stores. When a pharmacological agent activates the glucagon receptor at a sustained level, it may amplify these fasting-like metabolic signals even in the fed state, though the degree to which this occurs in humans at the doses used in retatrutide trials is still being characterised.

At the cellular level, glucagon receptor signalling works through cyclic AMP (cAMP) as a second messenger, activating protein kinase A and downstream pathways that regulate lipid and glucose metabolism.^[11][12] In the liver, this cascade is thought to upregulate enzymes involved in fatty acid oxidation and suppress lipogenic pathways, potentially reducing liver fat content. In brown adipose tissue, preclinical data suggest that glucagon receptor stimulation may increase uncoupling protein expression, promoting thermogenesis and raising overall energy expenditure, though robust human evidence for this specific effect remains limited.

These hepatic and thermogenic effects are considered clinically relevant because excess liver fat and reduced resting energy expenditure are both features of obesity and metabolic syndrome. However, the magnitude and durability of these effects in humans, and their clinical significance relative to the GLP-1 and GIP components of retatrutide, have not yet been fully characterised outside of trial settings. The interaction between all three receptor pathways is complex, and the net metabolic outcome depends on the relative potency at each receptor, the dose used, and individual patient factors. The GLP-1-mediated insulinotropic effect is intended to offset any glucagon-driven tendency towards raised blood glucose, but this balance continues to be evaluated in ongoing trials.

What have clinical trials reported about retatrutide's effects?

Phase 2 data published in 2023 reported dose-dependent body weight reductions and improvements in liver fat and cardiometabolic markers; Phase 3 TRIUMPH and TRANSCEND trials are generating larger-scale evidence.

Phase 2 trial data published in the New England Journal of Medicine in 2023 reported that participants with obesity who received retatrutide experienced dose-dependent reductions in body weight over 48 weeks, with outcomes varying by dose group within that trial population. The Phase 3 programme, which includes the TRIUMPH series (investigating retatrutide in people with obesity) and the TRANSCEND series (including TRANSCEND-T2D-1, investigating retatrutide in people with type 2 diabetes), is generating the larger-scale evidence that regulatory agencies will assess. Results from these studies are being presented at scientific congresses and published as they become available.

In the Phase 2 data, reductions in liver fat and improvements in cardiometabolic markers such as waist circumference, blood pressure and lipid levels were also reported in some participant groups.^[1][2] These findings are consistent with the proposed mechanism involving glucagon receptor-mediated hepatic fat reduction alongside GLP-1 and GIP receptor-mediated appetite suppression and insulin sensitisation. However, trial findings describe outcomes in defined research populations under controlled conditions and cannot be generalised as predictions of what any individual would experience.

It is also important to note that Phase 2 trials are designed primarily to assess safety, tolerability and dose-ranging rather than to confirm efficacy at a population level. The TRIUMPH and TRANSCEND Phase 3 trials are the appropriate evidence base for evaluating whether the effects observed in earlier research are reproducible and clinically meaningful at scale. Regulatory agencies including the MHRA will assess the totality of this evidence before any authorisation decision is made, and no timeline for that process can be stated.

What are the known and suspected side effects to watch for?

Gastrointestinal effects including nausea, vomiting and diarrhoea are most commonly reported; participants should also monitor for symptoms of pancreatitis, gallbladder events and contact their trial team promptly if these occur.

The side effects reported in retatrutide trials to date are broadly consistent with those seen across the GLP-1 receptor agonist class, with gastrointestinal effects being the most commonly reported. These include nausea, vomiting, diarrhoea and constipation, which tend to be most prominent during dose escalation and often reduce over time. If vomiting or diarrhoea is severe or prolonged and a participant is unable to keep fluids down, they should contact their trial team promptly, as dehydration can develop quickly.

GLP-1 receptor agonist class medicines have also been associated with gallbladder and biliary events.^[14][15] Participants should be aware of symptoms such as persistent pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice), and should contact their trial team promptly if any of these occur.

Pancreatitis has been reported in association with GLP-1 receptor agonist class medicines.^[14][16] Participants in retatrutide trials are monitored for symptoms including persistent severe abdominal pain. Anyone in a trial who develops such symptoms should contact their trial team immediately, as the study protocol governs how adverse events are managed and reported.

Because retatrutide trials exclude participants who are pregnant, breastfeeding or planning pregnancy, the safety profile in these groups is not established. Contraception requirements are specified within individual trial protocols, and participants of childbearing potential should follow the guidance given by their trial team. Anyone who becomes pregnant during a trial must inform the trial team without delay.

If any symptoms are severe or life-threatening, call 999 or go to the nearest accident and emergency department. When doing so, participants should inform emergency clinicians that they are taking part in a clinical trial and carry their trial identification or documentation with them. For urgent but non-emergency concerns, NHS 111 is available. Routine questions about trial participation should be directed to the trial team or a GP. Suspected side effects from medicines used within a clinical trial can also be reported to the MHRA via the Yellow Card scheme at yellowcard.^[17][18]mhra.gov.uk.

Frequently Asked Questions